Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
Status:
Terminated
Trial end date:
2011-01-18
Target enrollment:
Participant gender:
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such
as flutamide, bicalutamide, leuprolide, buserelin, and goserelin, may lessen the amount of
androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells.
Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
known whether giving androgen suppression therapy together with radiation therapy is more
effective with or without docetaxel in treating prostate cancer.
PURPOSE: This randomized phase III trial is studying androgen suppression therapy, radiation
therapy, and docetaxel to see how well they work compared with androgen suppression therapy
and radiation therapy in treating patients with high-risk localized prostate cancer.
CLOSURE: This trial closed to further accrual in November 2009. The study endpoints will not
be reached.